Aptahem has finalized an improved bioanalytical method for the measurement of Apta-1 in plasma
Aptahem is now able to announce that the development of a completely new bioanalysis method has been finalized in collaboration with our partner Axolab in Germany.
The new method has a better resolution and can detect lower levels of Apta-1 as well as its metabolites in the plasma of different animal species. The new method has been developed in accordance with the regulatory demands that are required for future toxicological tests and later in clinical trials. The method allows the levels of Apta-1 in mouse, rat, monkey and human plasma samples to be determined by PNA-HPLC (Peptide nucleic acid high pressure liquid chromatography) assay.
CEO Mikael Lindstam comments
-“The analysis of large aptamer molecules has been a challenge for the pharmaceutical industry for a long time, and I see this new method as an important milestone. By achieving this regulatory requirement, work can now proceed in preparation for our planned clinical study.”
For further information:
Mikael Lindstam, CEO, Aptahem AB
Tel: + 46 (0)766-33 36 99
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.